000096048 001__ 96048
000096048 005__ 20230914083234.0
000096048 0247_ $$2doi$$a10.3389/fphar.2019.00852
000096048 0248_ $$2sideral$$a112981
000096048 037__ $$aART-2019-112981
000096048 041__ $$aeng
000096048 100__ $$0(orcid)0000-0003-3392-7200$$aIrun, P.
000096048 245__ $$aOmega-3 Polyunsaturated Fatty Acids and Their Bioactive Metabolites in Gastrointestinal Malignancies Related to Unresolved Inflammation. A Review
000096048 260__ $$c2019
000096048 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096048 5203_ $$aChronic inflammation takes part in the pathogenesis of some malignancies of the gastrointestinal tract including colorectal (CRC), gastric, and esophageal cancers. The use of omega 3 polyunsaturated fatty acid (omega 3-PUFA) supplements for chemoprevention or adjuvant therapy of gastrointestinal cancers is being investigated in recent years. Most evidence has been reported in CRC, although their protective role has also been reported for Helicobacter pylori-induced gastric cancer or Barrett''s esophagus-derived adenocarcinoma. Studies based on omega 3-PUFA supplementation in animal models of familial adenomatous polyposis (FAP) and CRC revealed positive effects on cancer prevention, reducing the number and size of tumors, down-regulating arachidonic acid-derived eicosanoids, upregulating anti-oxidant enzymes, and reducing lipid peroxidation, whereas contradictory results have been found in induced colitis and colitis-associated cancer. Beneficial effects have also been found in FAP and ulcerative colitis patients. Of special interest is their positive effect as adjuvants on radio- and chemo-sensitivity, specificity, and prevention of treatment complications. Some controversial results obtained in CRC might be justified by different dietary sources, extraction and preparation procedures of omega 3-PUFAs, difficulties on filling out food questionnaires, daily dose and type of PUFAs, adenoma subtype, location of CRC, sex differences, and genetic factors. Studies using animal models of inflammatory bowel disease have confirmed that exogenous administration of active metabolites derived from PUFAs called pro-resolving mediators like lipoxin A4, arachidonic acid-derived, resolvins derived from eicosapentaenoic (EPA), docosahexaenoic (DHA), and docosapentaenoic (DPA) acids as well as maresin 1 and protectins DHA- and DPA-derived improve disease and inflammatory outcomes without causing immunosuppression or other side effects.
000096048 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01109
000096048 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000096048 590__ $$a4.225$$b2019
000096048 591__ $$aPHARMACOLOGY & PHARMACY$$b52 / 270 = 0.193$$c2019$$dQ1$$eT1
000096048 592__ $$a1.228$$b2019
000096048 593__ $$aPharmacology (medical)$$c2019$$dQ1
000096048 593__ $$aPharmacology$$c2019$$dQ1
000096048 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000096048 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000096048 700__ $$0(orcid)0000-0001-5813-3445$$aPiazuelo, E.$$uUniversidad de Zaragoza
000096048 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000096048 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000096048 773__ $$g10, 852 (2019), [12 pp]$$pFront. pharmacol.$$tFrontiers in Pharmacology$$x1663-9812
000096048 8564_ $$s312192$$uhttps://zaguan.unizar.es/record/96048/files/texto_completo.pdf$$yVersión publicada
000096048 8564_ $$s30759$$uhttps://zaguan.unizar.es/record/96048/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096048 909CO $$ooai:zaguan.unizar.es:96048$$particulos$$pdriver
000096048 951__ $$a2023-09-13-10:45:27
000096048 980__ $$aARTICLE